Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent antiarrhythmic drugs.

P Jaillon1, M Drici

  • 1Unité de Pharmacologie Clinique, Hôpital Saint-Antoine, Paris, France.

The American Journal of Cardiology
|December 5, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Follow-up of a 16-year-old adolescent with early-onset schizophrenia and catatonic symptoms].

L'Encephale·2012
Same author

[Comparison between two analgesic protocols on IVF success rates].

Journal de gynecologie, obstetrique et biologie de la reproduction·2010
Same author

Suicide attempts in a prospective cohort of patients with schizophrenia treated with sertindole or risperidone.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2010
Same author

[Management of atrial fibrillation in France: the observational FACTUEL study].

Annales de cardiologie et d'angeiologie·2009
Same author

[Treating heart failure with carvedilol in private practice (initiating treatment and follow-up at one year. The KEOPS study].

Archives des maladies du coeur et des vaisseaux·2007
Same author

Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics.

Clinical pharmacology and therapeutics·2007
Same journal

Real-World Effectiveness and Tolerability of Sacubitril/Valsartan in Octogenarian Patients With Heart Failure: Results From the PARACHUTER Study.

The American journal of cardiology·2026
Same journal

ECG-Guided Conduction Pathways as a Lever to Shorten Post-TAVI Hospitalization.

The American journal of cardiology·2026
Same journal

Cystatin-C versus creatinine and kidney function in heart failure with preserved ejection fraction: a SOGALDI-PEF analysis.

The American journal of cardiology·2026
Same journal

Balloon-expandable versus Self-expanding Valves in Patients with Small Aortic Annuli Undergoing Transcatheter Aortic Valve Replacement.

The American journal of cardiology·2026
Same journal

Drug-Coated Balloons versus Drug-Eluting Stents following Coronary Atherectomy in Severely Calcified Lesions: A Systematic Review and Meta-Analysis.

The American journal of cardiology·2026
Same journal

Prehospital Statin Therapy and Outcomes in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

The American journal of cardiology·2026
See all related articles

New antiarrhythmic drugs, including Class IC, show promise in suppressing ventricular arrhythmias but require further trials. Future treatments must balance efficacy with reduced toxicity and improved patient survival rates.

Area of Science:

  • Pharmacology
  • Cardiology
  • Drug Development

Background:

  • Clinical antiarrhythmic drug failure necessitates novel agents with improved efficacy, safety, and duration.
  • Current antiarrhythmic drugs primarily target myocardial cell sodium ion channels, with Class I agents categorized by their effects on channel recovery kinetics.

Purpose of the Study:

  • To review the pharmacologic properties and clinical effects of newly developed antiarrhythmic drugs across various classes.
  • To discuss the implications of new drug development for future antiarrhythmic therapy and patient outcomes.

Main Methods:

  • Review of existing literature on new antiarrhythmic drug classes (I, II, III, IV).
  • Analysis of drug classifications based on sodium ion channel effects and electrophysiologic profiles.

Related Experiment Videos

Main Results:

  • Class IC drugs are potent in suppressing ventricular premature beats but their impact on long-term survival is uncertain.
  • New agents in Class II (beta-blockers), Class III (action potential duration prolongers), and Class IV (mixed ion channel antagonists) have emerged.

Conclusions:

  • Future antiarrhythmic drug development must prioritize agents with novel electrophysiologic profiles and minimal adverse effects.
  • Large-scale clinical trials are crucial to determine if new drugs can reduce sudden cardiac death rates and improve patient survival.